valproic acid and Unverricht-Lundborg Syndrome

valproic acid has been researched along with Unverricht-Lundborg Syndrome in 9 studies

Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.

Unverricht-Lundborg Syndrome: An autosomal recessive condition characterized by recurrent myoclonic and generalized seizures, ATAXIA, slowly progressive intellectual deterioration, DYSARTHRIA, and intention tremor. Myoclonic seizures are severe and continuous, and tend to be triggered by movement, stress, and sensory stimuli. The age of onset is between 8 and 13 years, and the condition is relatively frequent in the Baltic region, especially Finland. (From Menkes, Textbook of Child Neurology, 5th ed, pp109-110)

Research

Studies (9)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Percent Change From Baseline to the End of Treatment Period on the Action Myoclonus Score (Unified Myoclonus Rating Scale (UMRS) Section 4)

The range for Action Myoclonus Score (centrally read) is 0 (best) - 160 (worst). Percent change from Baseline = 100 X ((Baseline UMRS4 - Treatment UMRS4) / Baseline UMRS4). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: From Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)

Percent Change From Baseline to the End of Treatment Period on the Functional Disability Score (Unified Myoclonus Rating Scale (UMRS) Section 5)

The range for Functional Disability Score is 0 (best) to 28 (worst). Percent change from Baseline = 100 X ((Baseline UMRS5 - Treatment UMRS5) / Baseline UMRS5). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)

Percent Change From Baseline to the End of Treatment Period on the Myoclonus Patient Questionnaire (Unified Myoclonus Rating Scale (UMRS) Section 1)

The range for Myoclonus Patient Questionnaire is 0 (best) to 44 (worst). Percent change from Baseline = 100 X ((Baseline UMRS1 - Treatment UMRS1) / Baseline UMRS1). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)

Percent Change From Baseline to the End of Treatment Period on the Stimulus Sensitivity Score (Unified Myoclonus Rating Scale (UMRS) Section 3)

The range for Stimulus Sensitivity Score is 0 (best) to 17 (worst). Percent change from Baseline = 100 X ((Baseline UMRS3 - Treatment UMRS3) / Baseline UMRS3). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)

Global Evaluation Score (Investigator) at the End of Treatment Period

The Global Evaluation Scale Score (Investigator) ranges from 1 (Marked worsening) to 7 (Marked improvement). (NCT00368251)
Timeframe: End of Treatment Period (Week 14 or Early Discontinuation Visit)

Reviews

2 reviews available for valproic acid and Unverricht-Lundborg Syndrome

Trials

2 trials available for valproic acid and Unverricht-Lundborg Syndrome

Other Studies

5 other studies available for valproic acid and Unverricht-Lundborg Syndrome